SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe4/2/2016 11:26:57 AM
1 Recommendation

Recommended By
mulanoon2007

   of 4474
 
Swedish study lays groundwork for briga in neuroblastoma...

"In summary, we show that brigatinib abrogates ALK activation in neuroblastoma cell lines, in vitro biochemical assays as well as exogenously expressed ALK activity in flies and mice xenografts. Taken together, our data indicate that brigatinib is a potent inhibitor against ALK, supporting further exploration of brigatinib in an ALK- positive neuroblastoma setting."

[Ariad's Victor Rivera is co-author]

impactjournals.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News